Ford Alfred J Jr sold $151K of KMTS

Ford Alfred J Jr (Chief Commercial Officer) sold 6,275 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $24.09 ($0.15M total) on 2026-08-04.

Original reporting
SEC EDGAR · Ford Alfred J Jr
Published Aug 6, 2026, 11:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The newest fact is the specific open-market sale by the CCO: 6,275 shares at $24.0862 on 2026-08-04, totaling $151,140.90, with post-sale holdings of 99,564 shares and no disclosed pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider selling as a sentiment datapoint, but the filing alone is unlikely to change valuation without corroborating company news.

03

What to watch

The filing does not state motivations, remaining option/RSU activity, or whether other insiders are buying/selling around the same period.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-06 after-hours; sale dated 2026-08-04

Background

The article is a primary-source SEC Form 4 insider transaction for Keystra Medical Technologies, Ltd. (KMTS).

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Insider Form 4 shows CCO Alfred J. Ford Jr sold 6,275 shares of KMTS for about $151.1K on 2026-08-04.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional fundamental signal from the filing alone.

Evidence & confidence

The disclosure is a Form 4 insider transaction, not earnings, guidance, or a corporate event. The article provides sale size and price but no accompanying company-specific news.

Market effects

Minimal. Insider sales in a single small-cap medical technology name typically do not reset sector expectations.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification, taxes, or planned liquidity needs; without a 10b5-1 plan, it still does not imply negative company fundamentals.

Key entities

  • KMTS

    Keystra Medical Technologies, Ltd., the company whose insider transaction is disclosed.

  • Ford Alfred J Jr

    Chief Commercial Officer who sold shares via an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KMTSMedAI 8/10

Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.